The Idiosyncratic Efficacy of Spironolactone-Loaded PLGA Nanoparticles Against Murine Intestinal Schistosomiasis

Abstract

Background Schistosomiasis is a chronic debilitating parasitic disease accompanied with severe mortality rates. Although praziquantel (PZQ) acts as the sole drug for the management of this disease, it has many limitations that restrict the use of this treatment approach. Repurposing of spironolactone (SPL) and nanomedicine represents a promising approach to improve anti-schistosomal therapy. We have developed SPL-loaded poly(lactic-co-glycolic acid) (PLGA) nanoparticles (NPs) to enhance the solubility, efficacy, and drug delivery and hence decrease the frequency of administration, which is of great clinical value. Methods The physico-chemical assessment was performed starting with particle size analysis and confirmed using TEM, FT-IR, DSC, and XRD. The antischistosomal effect of the SPL-loaded PLGA NPs against Schistosoma mansoni ( S. mansoni )-induced infection in mice was also estimated. Results Our results manifested that the optimized prepared NPs had particle size of 238.00 ± 7.21 nm, and the zeta potential was −19.66 ± 0.98 nm, effective encapsulation 90.43±8.81%. Other physico-chemical features emphasized that nanoparticles were completely encapsulated inside the polymer matrix. The in vitro dissolution studies revealed that SPL-loaded PLGA NPs showed sustained biphasic release pattern and followed Korsmeyer–Peppas kinetics corresponding to Fickian diffusion ( n <0.45). The used regimen was efficient against S. mansoni infection and induced significant reduction in spleen, liver indices, and total worm count ( ρ <0.05). Besides, when targeting the adult stages, it induced decline in the hepatic egg load and the small intestinal egg load by 57.75% and 54.17%, respectively, when compared to the control group. SPL-loaded PLGA NPs caused extensive damage to adult worms on tegument and suckers, leading to the death of the parasites in less time, plus marked improvement in liver pathology. Conclusion Collectively, these findings provided proof-of-evidence that the developed SPL-loaded PLGA NPs could be potentially used as a promising candidate for new antischistosomal drug development.

Nanotechnological approaches in the treatment of schistosomiasis: an overview

“…Moreover, they proved in mice that orally administered nanoformulation was efficient against S. mansoni infection and induced significant reduction in spleen, liver indices, and total worm count, and it induced decline in the hepatic and small intestinal egg load. Finally, it also caused extensive damage to adult worms on tegument and suckers, leading to the death of the parasites in less time compared to that for the drug alone, and improve liver pathology [ 75 ].…”

Genistein transfersome-embedded topical delivery system for skin melanoma treatment: in vitro and ex vivo evaluations

“…Subsequently, FTIR software for data processing (OMNIC version 8) was used to record, visualize and interpret the corresponding peaks. The average of triplicate sample measurements of the IR distinctive peaks spectra was attained (Abd El Hady et al., 2023 ).…”

“…Our data analysis curves were automatically generated via Calisto treatment software. Before every run, the baseline was optimized (Abd El Hady et al., 2023 ).…”

Electrospun multi‐chamber core–shell nanofibers and their controlled release behaviors: A review

“…Biphasic drug delivery systems demonstrate efficacy in addressing chronic diseases with complex treatment environments (Agrawal et al, 2023). Recent studies have proven that biphasic drug delivery systems hold a positive effect in the treatment of chronic schistosomiasis and chronic wounds (Abd El Hady et al, 2023; Hwang et al, 2023). Furthermore, this system has advantages in treating chronic inflammation (Wongrakpanich et al, 2023).…”